CNS Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CNS Pharmaceuticals, Inc. (CNSP)
CIK: 0001729427
Period of Report: 2021-02-05

Reporting Person: Downs Christopher (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-05	Option to purchase common stock (right to buy)	$3.36	A	131000	Acquired	2031-02-05	Common Stock (131000)	Direct

Footnotes

F1: The stock options set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date and are subject to the grantee's continued service to the Company on each vesting date.

F2: The stock options were issued in connection with the reporting person's employment with the Company.